Lupin shares are likely to remain in focus in Tuesday’s trading session after the pharmaceutical major received final approval from the US Food and Drug Administration (USFDA) for its generic version of Pitolisant Tablets, a drug used to treat excessive daytime sleepiness.
Lupin announced that the USFDA has granted final approval for its Abbreviated New Drug Application (ANDA) covering Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.